Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Sanuwave Health (NASDAQ: SNWV) will attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12 to January 15, 2026. The company offers FDA-approved next-generation wound care products and said management will be available for meetings during the conference.
Investors or parties wishing to meet should contact investors@sanuwave.com to schedule a time.
Positive
- None.
Negative
- None.
News Market Reaction – SNWV
In the Dec 10 session, SNWV gained 1.36%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Commercial access update | Positive | -8.6% | UltraMIST added as option for Healogics iSupply members. |
| Nov 07 | Earnings results | Positive | +17.7% | Record Q3 revenue, strong margins, and higher full-year outlook. |
| Nov 03 | Earnings call notice | Neutral | +0.3% | Announcement of Q3 2025 earnings call logistics and replay details. |
| Nov 03 | Reimbursement update | Neutral | -5.3% | CMS final 2026 fee schedule showing UltraMIST rates largely unchanged. |
| Oct 06 | Prelim earnings update | Negative | +9.1% | Preliminary Q3 revenue below prior guidance and lowered 2025 outlook. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has sometimes shown divergence, with positive commercial updates occasionally met by negative price reactions, while core earnings reports have generally aligned with positive moves.
Over the last few months, Sanuwave reported record Q3 2025 revenue around $11.5M with strong year-over-year growth and issued both preliminary and final results, generally drawing positive price reactions. A CMS reimbursement update for UltraMIST and the recent UltraMIST GPO addition produced mixed to negative short-term moves. Against that backdrop, this J.P. Morgan Healthcare Conference participation fits into an ongoing stream of commercial and investor-relations visibility events.
Key Terms
fda-approved regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased to announce that it will be attending the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 12th to January 15th 2026.
Those wishing to meet with company management during the conference should reach out to investors@sanuwave.com to schedule a time.
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as may be required by applicable law.
Contact: investors@sanuwave.com
